Idarubicin and Cytarabine with and without Midostaurin for FLT3-Mutated Acute Myeloid Leukemia

被引：0
|
作者：
Diebold, Kendall [1 ]
Worth, Sarah [2 ]
Bachiashvili, Kimo [2 ]
Vachhani, Pankit [3 ]
Rangaraju, Sravanti [1 ]
Espinoza-Gutarra, Manuel [1 ]
Al-Kadhimi, Zaid [1 ]
Bhatia, Ravi [1 ]
Jamy, Omer [4 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Birmingham, AL USA
[3] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Div Hematol Oncol, Birmingham, AL USA
[4] Univ Alabama Birmingham, Div Hematol & Oncol, Dept Med, Birmingham, AL USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185198
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Idarubicin and cytarabine with and without midostaurin for FLT3-mutated acute myeloid leukemia
    Diebold, Kendall
    Bourne, Garrett
    Espinoza-Gutarra, Manuel
    Al-Kadhimi, Zaid
    Bachiashvili, Kimo
    Rangaraju, Sravanti
    Vachhani, Pankit
    Bhatia, Ravi
    Jamy, Omer
    LEUKEMIA & LYMPHOMA, 2024, 65 (11) : 1737 - 1739
  • [2] Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia
    Lee, Julia S.
    Wagner, Charlotte B.
    Prelewicz, Stacy
    Kurish, Heena P.
    Walchack, Robert
    Cenin, Danielle A.
    Patel, Seema
    Lo, Mimi
    Schlafer, Danielle
    Li, Belinda K. T.
    Harvey III, R. Donald
    Wasef, Bestis
    Ying, Jian
    Kovacsovics, Tibor
    REVISTA CHILENA DE LITERATURA, 2023, (108): : 3460 - 3463
  • [3] Midostaurin in FLT3-Mutated Acute Myeloid Leukemia
    Sahoo, Ranjit K.
    Kumar, Lalit
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19): : 1901 - 1902
  • [4] Midostaurin in FLT3-Mutated Acute Myeloid Leukemia REPLY
    Stone, Richard M.
    Larson, Richard A.
    Doehner, Hartmut
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (19): : 1903 - 1903
  • [5] Midostaurin in FLT3-mutated acute myeloid leukaemia
    Das, Manjulika
    LANCET ONCOLOGY, 2017, 18 (08): : E439 - E439
  • [6] Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis
    Kayser, Sabine
    Levis, Mark J.
    Schlenk, Richard F.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1177 - 1189
  • [7] Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis
    Sly, Nichole
    Gaspar, Katie
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (05) : 268 - 274
  • [8] Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia
    Joudinaud, Romane
    Boudry, Augustin
    Fenwarth, Laurene
    Geffroy, Sandrine
    Salson, Mikael
    Dombret, Herve
    Berthon, Celine
    Pigneux, Arnaud
    Lebon, Delphine
    Peterlin, Pierre
    Bouzy, Simon
    Flandrin-Gresta, Pascale
    Tavernier, Emmanuelle
    Carre, Martin
    Tondeur, Sylvie
    Haddaoui, Lamya
    Itzykson, Raphael
    Bertoli, Sarah
    Bidet, Audrey
    Delabesse, Eric
    Hunault, Mathilde
    Recher, Christian
    Preudhomme, Claude
    Duployez, Nicolas
    Dumas, Pierre-Yves
    BLOOD ADVANCES, 2025, 9 (02) : 365 - 374
  • [9] Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis
    Gallogly, Molly M.
    Lazarus, Hillard M.
    Cooper, Brenda W.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (09) : 245 - 261
  • [10] FLT3-Mutated Acute Myeloid Leukemia Using a Novel Regimen of Gemtuzumab Ozogamicin and Midostaurin in Combination with Standard Cytarabine and Daunorubicin Induction Therapy
    Borate, Uma
    Kaempf, Andy
    Minnier, Jessica
    Misra, Shikha
    Goodyear, Shaun
    Meyers, Gabrielle
    Saultz, Jennifer N.
    Traer, Elie
    Swords, Ronan
    Cook, Rachel J.
    Avaylon, Sammantha
    Mackey, Melissa
    Norris, Brianna
    Walter, Roland B.
    BLOOD, 2021, 138
12345